ME Therapeutics Holdings Inc. (CSE: METX) has engaged Orbiton Financial Inc. to lead its investor relations and market-awareness programme, the company announced on November 9, 2026. The engagement is designed to broaden shareholder reach as the Vancouver-based biotechnology company advances its in vivo dual targeted chimeric antigen receptor (CAR) candidate toward a first-in-human clinical trial. The company is also pursuing a potential NASDAQ listing, making heightened investor visibility a strategic priority at this stage of its development.

Key Points

  • ME Therapeutics Holdings Inc. (CSE: METX, FSE: Q9T) is a Vancouver-based biotechnology company developing novel in vivo CAR and therapeutic mRNA cancer treatments.
  • The company has engaged Orbiton Financial Inc. to provide investor relations and market-awareness services under a 12-month agreement effective November 3, 2026.
  • Orbiton will receive US$2,800 per month; consultant Matthew Nelson has been granted options on 125,000 common shares at C$1.05 per share, vesting monthly over 12 months and exercisable until November 5, 2028.
  • Investors may be watching progress toward the company's first-in-human clinical trial and its stated intention to pursue a NASDAQ listing.

Orbiton Financial Mandate and Scope of Services for METX

Under the agreement signed November 5, 2026, Orbiton will develop ME Therapeutics' investor relations strategy, prepare investor communications and website content, and coordinate investor meetings, roadshows, and conferences. Outreach will be conducted across Instagram, LinkedIn, and X (formerly Twitter). Matthew Nelson, Chief Operating Officer of Orbiton, will serve in the consulting role of Vice President, Investor Relations on a non-employee, non-officer basis. Orbiton and Mr. Nelson are confirmed as arm's-length parties to the company. The agreement continues month-to-month after the initial 12-month term and may be terminated by either party on 30 days' notice.

Compensation Structure and Share Option Grant

ME Therapeutics will pay Orbiton US$2,800 per month plus pre-approved expenses for the duration of the engagement. In addition, Mr. Nelson has received options to purchase 125,000 common shares at an exercise price of C$1.05 per share, exercisable until November 5, 2028, with vesting occurring monthly over 12 months. The company confirmed that aside from these options, neither Orbiton nor any of its principals currently hold any direct or indirect interest in the company's securities. The release states there are no performance factors contained in the agreement.

In Vivo CAR Pipeline and NASDAQ Listing Strategy Drive IR Push

The engagement reflects ME Therapeutics' stated aim to generate broader market awareness as it progresses its in vivo dual targeted CAR candidate toward a first-in-human clinical trial. The company is also executing a strategy to pursue a potential NASDAQ exchange listing, according to the announcement. CEO Salim Dhanji, PhD, noted in the release that the in vivo CAR space continues to attract scientific and deal-making interest, and that the company is now prioritising market awareness as a parallel workstream alongside its research activities.